摘要
目的探讨驱动蛋白2a(Kif2a)与基质金属蛋白酶2(MMP-2)在肺鳞癌组织表达及其与临床病理特征的关系,进一步评价两者在肺鳞癌发生、发展中的作用及其之间的相关性。方法应用免疫组织化学PV-9000法,检测60例肺鳞癌组织和28例癌旁正常对照肺组织中Kif2a与MMP-2的表达情况,并结合临床和病理资料进行分析。结果肺鳞癌组织Kif2a与MMP-2的阳性表达率明显高于正常肺组织(χ~2=21.614、26.110,P<0.01);且阳性表达强度差异有极显著性(Z=-4.981、-5.250,P<0.01)。肺鳞癌组织中Kif2a与MMP-2的阳性表达与癌组织有无淋巴结转移及TNM分期有关(Z=-2.328^-2.046,P<0.05),而与病人的性别、年龄、肿瘤大小无关(P>0.05);Kif2a阳性表达与癌组织的分化程度无关(P>0.05),而MMP-2的阳性表达与癌组织的分化程度有关(Z=-2.078,P<0.05);肺鳞癌组织中Kif2a与MMP-2表达呈显著正相关(r=0.468,P<0.01)。结论 Kif2a、MMP-2共同促进肺鳞癌的发生发展、浸润及转移,可能为抑制肺鳞癌浸润转移的临床靶向治疗提供新指标。
Objective To investigate the expressions of Kinesin 2a（ Kif2a） and Matrix Metalloproteinase-2（ MMP-2） in lung squamous cell carcinoma（ LSCC） and their relation with its clinicopathological characteristics,and further assess the action of the two parameters on occurence and development of this malignancy as well as the correlatin between the two parameters. Me-thods Employing immunohistochemical PV-9000 method,expressions of Kif2a and MMP-2 were detected in 60 samples of LSCC and 28 samples of normal tisssue around the cancer. An analysis was conducted combining clinical and pathological data. Results The expressions of Kif2a and MMP-2 in tissue of LSCC were significantly higher than that in the normal lung tissue（ χ~2= 21. 614,26. 110; P 〈 0. 01）,and the difference in intensity of positive expression was significant（ Z =- 4. 981,- 5. 250; P 〈 0. 01）. The positive expressions of Kif2a and MMP-2 in LSCC were associated with whether or not with lymph node metastasis and TNM staging（ Z =- 2. 328-- 2. 046,P 〈 0. 05）,but nothing to do with patient’s age and gender and the size of cancer（ P 〉 0. 05）. The positive expression of Kif2a was not associated with cancer tissue differentiation（ P 〉 0. 05）,but that of MMP-2 was associated with（ Z =- 2. 078,P 〈 0. 05）. In tissue of LSCC,the expression of kif2 a was positively correlated with MMP-2（ r = 0. 468,P 〈 0. 01）. Conclusion Both Kif2a and MMP-2 jointly promote the occurrence,development,invasion and metastasis of lung squamous cell carcinoma,which may provide a new targeted therapy for inhibiting infiltration and metastasis of this malignancy.
出处
《齐鲁医学杂志》
2016年第3期285-287,293,共4页
Medical Journal of Qilu
